RepliCel Life Sciences Inc.

DB:P6P2 Stock Report

Market Cap: €12.5k

RepliCel Life Sciences Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of P6P2?
Owner TypeNumber of SharesOwnership Percentage
Private Companies9,344,58414.4%
General Public23,063,90535.5%
Individual Insiders32,593,07150.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 12 shareholders own 64.52% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
26.8%
Andrew Schutte
17,401,616€3.3k0%no data
15.4%
Jamie MacKay
10,034,537€1.9k0%no data
8.24%
YOFOTO (China) Health Industry Co. Ltd.
5,357,900€1.0k0%no data
6.13%
Mainpointe Pharmaceuticals, LLC
3,986,684€765.70%no data
2.04%
Kevin McElwee
1,329,245€255.30%no data
1.84%
Peter Lowry
1,193,426€229.20%no data
1.35%
David Hall
875,632€168.20%no data
0.96%
Peter Lewis
626,920€120.40%no data
0.75%
Rolf Hoffmann
489,572€94.00%no data
0.49%
Ben Austring
320,500€61.60%no data
0.48%
Gary Boddington
314,815€60.50%no data
0.01%
R. Buckler
6,808€1.30%no data